RELMADA THERAPEUTICS, INC. 8-K

What Happened

• Relmada Therapeutics, Inc. announced on May 12, 2026 that it issued a press release providing a corporate update and reporting its financial results for the three months ended March 31, 2026. The company scheduled a conference call and audio webcast for May 12, 2026 at 4:30 PM EST / 1:30 PM PST to discuss the results and update.
• The company said its complete unaudited condensed consolidated financial statements and related notes as of March 31, 2026 and December 31, 2025, and for the three months ended March 31, 2026 and 2025, will be included in its Quarterly Report on Form 10‑Q to be filed with the SEC.

Key Details

• Filing date: May 12, 2026 (Current Report on Form 8‑K, Items 2.02 and 7.01).
• Reported period: three months ended March 31, 2026 (quarterly results/earnings disclosure).
• Investor event: conference call and audio webcast on May 12, 2026 at 4:30 PM EST / 1:30 PM PST.
• Materials furnished: press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2) were furnished with the 8‑K.

Why It Matters

• The 8‑K confirms Relmada has publicly released its quarterly earnings update and supporting presentation; investors should review the press release and slide deck for headline results and operational updates.
• For full financial detail, including the unaudited condensed consolidated statements and notes, investors should wait for the company’s upcoming Form 10‑Q filing, which will contain the complete quarterly financials and disclosures.